Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Richard A. Young sold 3,282 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $22.00, for a total transaction of $72,204.00. Following the sale, the director now directly owns 420,101 shares of the company’s stock, valued at approximately $9,242,222. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of Syros Pharmaceuticals, Inc. (SYRS) traded down 6.27% during trading on Wednesday, reaching $20.93. 117,065 shares of the company traded hands. The stock’s market capitalization is $549.62 million. Syros Pharmaceuticals, Inc. has a 12-month low of $10.22 and a 12-month high of $24.38. The firm’s 50-day moving average is $19.83 and its 200-day moving average is $15.67.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its earnings results on Wednesday, August 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.03. On average, equities analysts predict that Syros Pharmaceuticals, Inc. will post ($2.09) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/08/16/syros-pharmaceuticals-inc-syrs-director-richard-a-young-sells-3282-shares.html.

A number of large investors have recently made changes to their positions in SYRS. Wells Fargo & Company MN bought a new stake in shares of Syros Pharmaceuticals during the first quarter valued at about $225,000. Bank of New York Mellon Corp bought a new stake in shares of Syros Pharmaceuticals during the first quarter valued at about $185,000. Redmile Group LLC raised its stake in shares of Syros Pharmaceuticals by 0.5% in the first quarter. Redmile Group LLC now owns 952,740 shares of the company’s stock valued at $15,177,000 after buying an additional 4,300 shares during the last quarter. Schwab Charles Investment Management Inc. bought a new stake in shares of Syros Pharmaceuticals during the second quarter valued at about $343,000. Finally, Rhumbline Advisers bought a new stake in shares of Syros Pharmaceuticals during the second quarter valued at about $198,000. Institutional investors and hedge funds own 49.66% of the company’s stock.

A number of analysts have recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and set a $22.84 price target (down previously from $25.00) on shares of Syros Pharmaceuticals in a report on Thursday, August 10th. JMP Securities downgraded shares of Syros Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, August 10th. Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. ValuEngine raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a report on Wednesday, August 9th. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Syros Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $20.81.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.